Search results
Results from the WOW.Com Content Network
Generally, drugs outlined within the ATC code A should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Gastrointestinal system drugs .
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel diseaseBiological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
Most of these medications are benzimidazole derivatives, related to omeprazole, but imidazopyridine derivatives such as tenatoprazole have also been developed. [77] Potassium-competitive inhibitors such as revaprazan reversibly block the potassium-binding site of the proton pump, acting more quickly, but are not available in most countries.
There are a number of non-infectious causes of inflammation of the gastrointestinal tract. [1] Some of the more common include medications (like NSAIDs), certain foods such as lactose (in those who are intolerant), and gluten (in those with celiac disease). Crohn's disease is also a non-infectious cause of (often severe) gastroenteritis. [1]
The committee's recommendation will be considered by the FDA in its review of the company's NDA. The Prescription Drug User Fee Act (PDUFA) date for completion of the review is December 30, 2012.
Gastrointestinal diseases (abbrev. GI diseases or GI illnesses) refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum; and the accessory organs of digestion, the liver, gallbladder, and pancreas. Deaths due to digestive diseases per million persons in 2012
The main adverse drug reactions (ADRs) associated with NSAID use relate to direct and indirect irritation of the gastrointestinal (GI) tract. NSAIDs cause a dual assault on the GI tract: the acidic molecules directly irritate the gastric mucosa, and inhibition of COX-1 and COX-2 reduces the levels of protective prostaglandins. [40]
“Most studies examined taking echinacea for anywhere from 10 days to 5 months. The most common adverse effect was a mild gastrointestinal reaction that didn’t require medical care,” says Koenig.